Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States. [electronic resource]
Producer: 20200625Description: 1177-1193 p. digitalISSN:- 1179-2027
- Adult
- Antibodies, Bispecific -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Cost-Benefit Analysis
- Disease-Free Survival
- Female
- Humans
- Inotuzumab Ozogamicin -- administration & dosage
- Male
- Middle Aged
- Models, Economic
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Quality-Adjusted Life Years
- Randomized Controlled Trials as Topic
- United States
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.